Understanding how reduced DNA methylation affects cancer and gene activity
Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs
This study is looking at how changes in DNA can affect how genes that help fight tumors work, and it's being done by a researcher at the Dana-Farber Cancer Institute who is training to become an expert in cancer research, with the hope that what they learn could lead to new ways to treat cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11054590 on NIH RePORTER |
What this research studies
This research investigates how decreased DNA methylation influences the organization of the genome and the activation of genes that suppress tumors. By utilizing advanced techniques such as microscopy and CRISPR, the research aims to uncover the mechanisms behind these changes in cancer cells. The project is led by a clinical fellow at the Dana-Farber Cancer Institute, who is receiving mentorship and training to develop skills necessary for a future career in cancer research. The findings could provide insights into new therapeutic strategies for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with solid tumors that exhibit DNA hypomethylation.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not show DNA hypomethylation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new approaches for enhancing anti-tumor immunity and improving cancer treatment outcomes.
How similar studies have performed: Previous research has shown promising results in understanding the role of DNA methylation in cancer, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Johnstone, Sarah E — Dana-Farber Cancer Inst
- Study coordinator: Johnstone, Sarah E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.